← Back to Screener
ADC Therapeutics SA (ADCT)
Price$4.38
Favorite Metrics
Price vs S&P 500 (26W)-7.73%
Price vs S&P 500 (4W)3.16%
Market Capitalization$555.18M
All Metrics
Book Value / Share (Quarterly)$0.47
P/TBV (Annual)3.97x
Revenue Growth (3Y)-27.09%
Cash Flow / Share (Quarterly)$-1.12
Price vs S&P 500 (YTD)21.15%
Gross Margin (TTM)92.87%
Net Profit Margin (TTM)-175.31%
EPS (TTM)$-1.26
10-Day Avg Trading Volume0.92M
EPS Excl Extra (TTM)$-1.26
Revenue Growth (5Y)98.48%
EPS (Annual)$-1.12
ROI (Annual)-37.24%
Gross Margin (Annual)92.87%
Net Profit Margin (5Y Avg)-299.19%
Cash / Share (Quarterly)$2.08
Revenue Growth QoQ (YoY)36.36%
ROA (Last FY)-44.14%
Revenue Growth TTM (YoY)14.85%
EBITD / Share (TTM)$-0.80
ROE (5Y Avg)-117.97%
Operating Margin (TTM)-149.34%
Cash Flow / Share (Annual)$-1.12
P/B Ratio14.73x
P/B Ratio (Quarterly)4.17x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)9.00x
Net Interest Coverage (TTM)-2.26x
ROA (TTM)-47.26%
EPS Incl Extra (Annual)$-1.12
Current Ratio (Annual)4.37x
Quick Ratio (Quarterly)4.23x
3-Month Avg Trading Volume0.96M
52-Week Price Return261.16%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.30
P/S Ratio (Annual)6.82x
Asset Turnover (Annual)0.25x
52-Week High$4.98
Operating Margin (5Y Avg)-284.41%
EPS Excl Extra (Annual)$-1.12
CapEx CAGR (5Y)-37.69%
Tangible BV CAGR (5Y)-21.14%
26-Week Price Return-3.74%
Quick Ratio (Annual)4.23x
13-Week Price Return14.40%
Total Debt / Equity (Annual)3.72x
Current Ratio (Quarterly)4.37x
Enterprise Value$731.823
Revenue / Share Growth (5Y)89.29%
Asset Turnover (TTM)0.27x
Book Value / Share Growth (5Y)-19.47%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.51x
Pretax Margin (Annual)-174.06%
Cash / Share (Annual)$2.08
3-Month Return Std Dev66.16%
Gross Margin (5Y Avg)95.14%
Net Income / Employee (TTM)$-1
ROE (Last FY)-175.65%
Net Interest Coverage (Annual)-2.26x
EPS Basic Excl Extra (Annual)$-1.12
Receivables Turnover (TTM)3.29x
Total Debt / Equity (Quarterly)9.01x
EPS Incl Extra (TTM)$-1.26
Receivables Turnover (Annual)3.29x
ROI (TTM)-48.19%
P/S Ratio (TTM)6.82x
Pretax Margin (5Y Avg)-298.20%
Revenue / Share (Annual)$0.64
Tangible BV / Share (Annual)$0.92
Price vs S&P 500 (52W)231.33%
Year-to-Date Return23.80%
5-Day Price Return16.22%
EPS Normalized (Annual)$-1.12
ROA (5Y Avg)-45.50%
Net Profit Margin (Annual)-175.31%
Month-to-Date Return16.53%
Cash Flow / Share (TTM)$-2.16
EBITD / Share (Annual)$-0.77
Operating Margin (Annual)-149.34%
LT Debt / Equity (Annual)3.49x
ROI (5Y Avg)-69.52%
LT Debt / Equity (Quarterly)8.32x
EPS Basic Excl Extra (TTM)$-1.26
P/TBV (Quarterly)6.53x
P/B Ratio (Annual)3.33x
Inventory Turnover (TTM)0.51x
Pretax Margin (TTM)-174.06%
Book Value / Share (Annual)$1.10
Price vs S&P 500 (13W)13.71%
Beta1.99x
Revenue / Share (TTM)$0.54
ROE (TTM)-229.23%
52-Week Low$1.13
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ADCTADC Therapeutics SA | 6.82x | 14.85% | 92.87% | — | $4.38 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
ADC Therapeutics is an oncology-focused biotechnology company with an FDA-approved product, ZYNLONTA, for relapsed or refractory large B-cell lymphoma. The company develops antibody-drug conjugates (ADCs) targeting hematological malignancies and solid tumors, supported by a pipeline of candidates across multiple mechanisms. Revenue is generated primarily from the United States and Europe.